Developer docs
API playgroundTry for free, no card

Search company profiles

Qpex Biopharma

Full company profile

uuid0007gr4

Namestring
Qpex Biopharma
Legal namestring
Qpex Biopharma, Inc.
Websiteurl
qpexbio.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Qpex Biopharma is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in San Diego, California, developing a pipeline of novel anti-infective therapies to address antimicrobial resistance (AMR). The company is a wholly owned subsidiary of Shionogi Inc. following a 2023 acquisition by the Japanese pharmaceutical group. Its core scientific platform centers on xeruborbactam (formerly QPX7728), an internally discovered ultra-broad-spectrum beta-lactamase inhibitor active across Class A, B, C, and D enzymes including metallo-beta-lactamases, which restores the potency of multiple beta-lactam antibiotics against drug-resistant gram-negative pathogens. Xeruborbactam is the basis for two clinical product formats: OMNIvance (IV-administered, targeting carbapenem-resistant Acinetobacter, Enterobacteriaceae, and Pseudomonas in inpatient settings) and ORAvance (an oral combination for outpatient and community infections caused by ESBL- and carbapenemase-producing Enterobacterales). A separate clinical asset, QPX9003, is a next-generation synthetic lipopeptide antibiotic positioned as a reduced-nephrotoxicity alternative to polymyxin B and colistin for highly drug-resistant Pseudomonas and Acinetobacter.

Qpex generates revenue through a mix of government grant funding, strategic licensing, and milestone payments rather than product sales. BARDA has provided up to $132 million under an Other Transaction Authority agreement, with approximately $92 million awarded through May 2024 in staged options. A multi-product collaboration with Brii Biosciences granted greater China rights in exchange for upfront payments, development and commercial milestones, cost-sharing, and tiered royalties. Partnerships with GARDP and CHAI extend access to cefiderocol in 135 low- and middle-income countries. All three pipeline products have received QIDP designation from FDA, providing eligibility for fast-track review and regulatory exclusivity extensions. Following Shionogi's 2023 acquisition, Qpex serves as the U.S.-based anti-infective R&D arm of the group, expanded in April 2025 with a new drug discovery laboratory in San Diego that is the first such U.S. facility within the Shionogi Group. Customers currently consist of government health agencies (BARDA, Project BioShield), strategic commercialization partners (Brii, GARDP, CHAI), and ultimately upon approval, hospital systems treating serious drug-resistant bacterial infections.

Short descriptiontext

Qpex Biopharma is a Shionogi-owned, San Diego-based clinical-stage biopharma developing novel antibiotics, led by xeruborbactam-based IV and oral therapies and QPX9003, to address drug-resistant gram-negative bacterial infections for hospital, outpatient, and government biodefense customers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antimicrobial drug discovery, beta-lactamase inhibitors, anti-infective therapeutics, clinical-stage antibiotics, gram-negative infection treatment
Industry2 codes
PRIMARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAFAG
Microbiome Modulating Small Molecules & Antibiotic Alternatives
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Anti-infective Pharmaceuticals
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Antibiotic Development and Commercialization
TypeOne Time License
Description

As a clinical-stage biopharmaceutical company, Qpex Biopharma generates revenue through the development and eventual commercialization of novel anti-infective therapeutics. The company has received QIDP (Qualified Infectious Disease Product) designation from FDA for all three pipeline products, which provides regulatory exclusivity extensions and eligibility for fast-track designation.

qpexbio.com
2Partnership and Licensing Revenue
TypeLicensing Royalties
Description

Qpex has strategic partnerships including a multi-product collaboration with Brii Biosciences for development and commercialization of three products in greater China (Taiwan, Hong Kong, Macau, and PRC), receiving upfront payments, milestone payments, and tiered royalties on sales.

qpexbio.com
3Government Contract Revenue
TypeProfessional Services
Description

The company receives funding through BARDA public-private partnerships under Other Transaction Authority agreements for development of antibiotics addressing drug-resistant infections. BARDA has provided funding up to $132 million total if all options are awarded.

qpexbio.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1OMNIvance
Description

An IV-administered xeruborbactam-based product with best-in-class coverage of key pathogens including carbapenem-resistant Acinetobacter, Enterobacteriaceae and Pseudomonas.

qpexbio.com
+2 more records
Core offering1 text field

Qpex Biopharma is a clinical-stage biopharmaceutical company that discovers and develops a pipeline of novel anti-infective therapies targeting drug-resistant gram-negative bacteria. Its portfolio is anchored by xeruborbactam, an investigational ultra-broad-spectrum beta-lactamase inhibitor that enables both an IV product (OMNIvance) for inpatient hospital use and an oral product (ORAvance) for outpatient and community use. A third program, QPX9003, is a next-generation synthetic lipopeptide antibiotic designed to address highly drug-resistant Pseudomonas and Acinetobacter infections with an improved toxicity profile compared to existing polymyxins.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • QPX9003 showed reduced nephrotoxicity compared to polymyxin B and colistin in preclinical studies
+2 more records
Product overview1 text field

Qpex Biopharma is a clinical-stage biopharmaceutical company developing a pipeline of novel anti-infective therapies to address antimicrobial resistance. The company's core product portfolio centers on xeruborbactam, an investigational ultra-broad-spectrum beta-lactamase inhibitor that enables multiple product formulations. OMNIvance delivers xeruborbactam via IV administration for inpatient use, while ORAvance provides an oral formulation for outpatient and community settings. QPX9003 is a next-generation synthetic lipopeptide antibiotic targeting highly drug-resistant Pseudomonas and Acinetobacter infections. All products target drug-resistant gram-negative bacteria considered serious-to-urgent antimicrobial resistance threats by the CDC.

Product and service3 records
1OMNIvance
CategoryAnti-infective Pharmaceuticals
Description

IV-administered xeruborbactam-based combination product designed to provide best-in-class coverage of key drug-resistant pathogens including carbapenem-resistant Acinetobacter, Enterobacterales, and Pseudomonas aeruginosa in inpatient hospital settings.

2ORAvance
CategoryAnti-infective Pharmaceuticals
Description

Orally-administered xeruborbactam-based combination product intended to treat infections in outpatient and community settings caused by drug-resistant gram-negative bacteria, offering an oral alternative to fluoroquinolones and IV therapy.

3QPX9003
CategoryAnti-infective Pharmaceuticals
Description

Next-generation IV-administered synthetic lipopeptide antibiotic with an enhanced therapeutic profile designed to address highly drug-resistant Pseudomonas and Acinetobacter infections, featuring reduced nephrotoxicity and improved pharmacological properties versus polymyxin B and colistin.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-09-25
Description

Shionogi joined the World Economic Forum in April 2026 and signed the Davos Compact on Antimicrobial Resistance, contributing to global efforts to address AMR through international collaboration with leaders from business, government, academia, and civil society.

2Kenyan Ministry of Health
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-07-18
Description

Collaboration to facilitate introduction of cefiderocol in Kenya. Shionogi and GARDP submitted Letter of Intent and project Concept Note to Kenyan Ministry of Health, which were accepted. Part of broader efforts for antimicrobial stewardship in Kenya.

qpexbio.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-05-31
Description

Qpex's partnership with BARDA under Other Transaction Authority (OTA) agreement (HHSO100201600026C) provides up to $132 million in federal funding for development of antibiotics to fight drug-resistant gram-negative infections. BARDA has awarded $92 million to date with technical support. The partnership has led to the first approved antimicrobial drug product under BARDA programs in 2017 and continues to advance Qpex's xeruborbactam-based products.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-06-26
Description

Shionogi acquired Qpex in 2023 to strengthen its antibiotic R&D capabilities and expand its anti-infective pipeline. The acquisition brought Qpex's expertise in antibiotic R&D along with its novel, internally discovered pipeline including xeruborbactam. Qpex continues to operate as a wholly owned Shionogi Group Company with expanded U.S.-based R&D operations.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2022-06-01
Description

Landmark license and technology transfer agreement with GARDP to expand access to cefiderocol in 135 countries. Part of efforts to transform access to antibiotics in low- and middle-income countries.

Strategic tierMajorTypeGTM or Marketing PartnerAnnounced on2022-06-01
Description

Collaboration agreement with CHAI as part of efforts to expand access to cefiderocol in low- and middle-income countries through pricing, distribution, and healthcare system support.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-01-19
Description

Multi-product collaboration for development and commercialization of three Qpex products (including xeruborbactam-based products) in greater China (Taiwan, Hong Kong, Macau, and PRC). Qpex retained all other rights globally. Terms include upfront payment, success-based development, regulatory and commercial milestone payments, cost sharing in global development program, and tiered royalties on sales in Brii territory.

8Monash University
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2021-06-17
Description

Research collaboration for development of QPX9003, a next-generation synthetic polymyxin. QPX9003 was discovered through NIAID-supported drug discovery collaboration with Professor Jian Li's team at Monash University's Antimicrobial Systems Pharmacology Laboratory. Funded by NIAID grants R01AI098771 and AI132154.

qpexbio.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Antibiotic developer of Nuzyra (omadacycline), acquired by Innoviva in 2023. Comparable as a small-cap antibiotic company with BARDA partnerships and novel mechanism anti-infectives targeting resistant pathogens.

TypeDirect peer
Description

Developer of Xerava (eravacycline), acquired by La Jolla Pharmaceutical Company in 2020. Directly comparable as a clinical-stage antibiotic company targeting multidrug-resistant infections, providing a cautionary commercial trajectory.

TypeDirect peer
Description

Clinical and commercial-stage antibiotic company developing treatments for drug-resistant infections, including approved products like Baxdela and Orbactiv. Directly comparable as a small-cap anti-infectives company navigating the same challenging commercial economics.

TypeOthers
Description

Former biopharmaceutical company that developed Zemdri (plazomicin) and received BARDA funding similar to Qpex. Filed for bankruptcy in 2019 despite FDA approval, illustrating the structural commercial challenges facing novel antibiotic developers in the current market environment.

TypeBroad incumbent
Description

Japanese multinational pharmaceutical company and Qpex's parent organization. Develops and commercializes cefiderocol (Fetroja), the leading siderophore cephalosporin antibiotic. Comparable as the established global anti-infectives player whose resources and pipeline now include Qpex's assets.

6Nabriva Therapeutics
TypeDirect peer
Description

Biopharmaceutical company that developed Xenleta (lefamulin), a first-in-class pleuromutilin antibiotic for community-acquired bacterial pneumonia. Comparable as a small anti-infectives company navigating commercial challenges post-approval.

TypeDirect peer
Description

Clinical-stage pharmaceutical company developing sulopenem (oral and IV) for drug-resistant infections including complicated UTIs. Directly comparable as a small clinical-stage antibiotic developer with similar regulatory pathway challenges.

TypeEmerging player
Description

Biopharmaceutical company developing anti-infectives including Cloudbreak antiviral conjugates and rezafungin antifungal. Comparable as an early-commercial anti-infectives company with novel mechanism approaches to resistant pathogens.

TypeEmerging player
Description

Private clinical-stage pharmaceutical company developing novel antibiotics to combat drug-resistant infections, including ceftibuten-ledaborbactam combination. Comparable as an emerging antibiotic developer with similar beta-lactamase inhibitor approach.

TypeDirect peer
Description

Anti-infectives company developing targeted therapies for drug-resistant infections, including sulbactam-durlobactam for Acinetobacter. Acquired by Innoviva in 2022. Comparable as a precision antibiotic developer with similar AMR focus.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Qpex Biopharma

Anti-infective Pharmaceuticalsqpexbio.com

Qpex Biopharma is a Shionogi-owned, San Diego-based clinical-stage biopharma developing novel antibiotics, led by xeruborbactam-based IV and oral therapies and QPX9003, to address drug-resistant gram-negative bacterial infections for hospital, outpatient, and government biodefense customers.

What Qpex Biopharma does

Qpex Biopharma is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in San Diego, California, developing a pipeline of novel anti-infective therapies to address antimicrobial resistance (AMR). The company is a wholly owned subsidiary of Shionogi Inc. following a 2023 acquisition by the Japanese pharmaceutical group. Its core scientific platform centers on xeruborbactam (formerly QPX7728), an internally discovered ultra-broad-spectrum beta-lactamase inhibitor active across Class A, B, C, and D enzymes including metallo-beta-lactamases, which restores the potency of multiple beta-lactam antibiotics against drug-resistant gram-negative pathogens. Xeruborbactam is the basis for two clinical product formats: OMNIvance (IV-administered, targeting carbapenem-resistant Acinetobacter, Enterobacteriaceae, and Pseudomonas in inpatient settings) and ORAvance (an oral combination for outpatient and community infections caused by ESBL- and carbapenemase-producing Enterobacterales). A separate clinical asset, QPX9003, is a next-generation synthetic lipopeptide antibiotic positioned as a reduced-nephrotoxicity alternative to polymyxin B and colistin for highly drug-resistant Pseudomonas and Acinetobacter.

Qpex generates revenue through a mix of government grant funding, strategic licensing, and milestone payments rather than product sales. BARDA has provided up to $132 million under an Other Transaction Authority agreement, with approximately $92 million awarded through May 2024 in staged options. A multi-product collaboration with Brii Biosciences granted greater China rights in exchange for upfront payments, development and commercial milestones, cost-sharing, and tiered royalties. Partnerships with GARDP and CHAI extend access to cefiderocol in 135 low- and middle-income countries. All three pipeline products have received QIDP designation from FDA, providing eligibility for fast-track review and regulatory exclusivity extensions. Following Shionogi's 2023 acquisition, Qpex serves as the U.S.-based anti-infective R&D arm of the group, expanded in April 2025 with a new drug discovery laboratory in San Diego that is the first such U.S. facility within the Shionogi Group. Customers currently consist of government health agencies (BARDA, Project BioShield), strategic commercialization partners (Brii, GARDP, CHAI), and ultimately upon approval, hospital systems treating serious drug-resistant bacterial infections.

Qpex Biopharma firmographics

Firmographics
Name
Qpex Biopharma
Legal name
Qpex Biopharma, Inc.
Website
https://qpexbio.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
Qpex Biopharma is a Shionogi-owned, San Diego-based clinical-stage biopharma developing novel antibiotics, led by xeruborbactam-based IV and oral therapies and QPX9003, to address drug-resistant gram-negative bacterial infections for hospital, outpatient, and government biodefense customers.
Ownership category
akta.pro rank

Qpex Biopharma industry classification

Industry
Product category
Anti-infective Pharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAFAG
Microbiome Modulating Small Molecules & Antibiotic Alternatives

Keywords

  • Antimicrobial drug discovery
  • Beta-lactamase inhibitors
  • Anti-infective therapeutics
  • Clinical-stage antibiotics
  • Gram-negative infection treatment

Where Qpex Biopharma is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Qpex Biopharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Antibiotic Development and Commercialization: As a clinical-stage biopharmaceutical company, Qpex Biopharma generates revenue through the development and eventual commercialization of novel anti-infective therapeutics. The company has received QIDP (Qualified Infectious Disease Product) designation from FDA for all three pipeline products, which provides regulatory exclusivity extensions and eligibility for fast-track designation.
  2. Partnership and Licensing Revenue: Qpex has strategic partnerships including a multi-product collaboration with Brii Biosciences for development and commercialization of three products in greater China (Taiwan, Hong Kong, Macau, and PRC), receiving upfront payments, milestone payments, and tiered royalties on sales.
  3. Government Contract Revenue: The company receives funding through BARDA public-private partnerships under Other Transaction Authority agreements for development of antibiotics addressing drug-resistant infections. BARDA has provided funding up to $132 million total if all options are awarded.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Qpex Biopharma product offering

Product offering

Core offering

Qpex Biopharma is a clinical-stage biopharmaceutical company that discovers and develops a pipeline of novel anti-infective therapies targeting drug-resistant gram-negative bacteria. Its portfolio is anchored by xeruborbactam, an investigational ultra-broad-spectrum beta-lactamase inhibitor that enables both an IV product (OMNIvance) for inpatient hospital use and an oral product (ORAvance) for outpatient and community use. A third program, QPX9003, is a next-generation synthetic lipopeptide antibiotic designed to address highly drug-resistant Pseudomonas and Acinetobacter infections with an improved toxicity profile compared to existing polymyxins.

Product overview

Qpex Biopharma is a clinical-stage biopharmaceutical company developing a pipeline of novel anti-infective therapies to address antimicrobial resistance. The company's core product portfolio centers on xeruborbactam, an investigational ultra-broad-spectrum beta-lactamase inhibitor that enables multiple product formulations. OMNIvance delivers xeruborbactam via IV administration for inpatient use, while ORAvance provides an oral formulation for outpatient and community settings. QPX9003 is a next-generation synthetic lipopeptide antibiotic targeting highly drug-resistant Pseudomonas and Acinetobacter infections. All products target drug-resistant gram-negative bacteria considered serious-to-urgent antimicrobial resistance threats by the CDC.

Differentiator

Problem solved

Functional benefit

Brands

  • OMNIvance: An IV-administered xeruborbactam-based product with best-in-class coverage of key pathogens including carbapenem-resistant Acinetobacter, Enterobacteriaceae and Pseudomonas.
  • ORAvance
  • QPX9003

Products and services

  • OMNIvance IV-administered xeruborbactam-based combination product designed to provide best-in-class coverage of key drug-resistant pathogens including carbapenem-resistant Acinetobacter, Enterobacterales, and Pseudomonas aeruginosa in inpatient hospital settings.
  • ORAvance Orally-administered xeruborbactam-based combination product intended to treat infections in outpatient and community settings caused by drug-resistant gram-negative bacteria, offering an oral alternative to fluoroquinolones and IV therapy.
  • QPX9003 Next-generation IV-administered synthetic lipopeptide antibiotic with an enhanced therapeutic profile designed to address highly drug-resistant Pseudomonas and Acinetobacter infections, featuring reduced nephrotoxicity and improved pharmacological properties versus polymyxin B and colistin.

Quantifiable outcome

  • QPX9003 showed reduced nephrotoxicity compared to polymyxin B and colistin in preclinical studies
  • +2 more outcomes

Companies that use Qpex Biopharma

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Qpex Biopharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Qpex Biopharma partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered minor, core and major.

  • World Economic ForumminorStrategic or Co-development Partner · 25 September 2025Shionogi joined the World Economic Forum in April 2026 and signed the Davos Compact on Antimicrobial Resistance, contributing to global efforts to address AMR through international collaboration with leaders from business, government, academia, and civil society.
  • Kenyan Ministry of HealthminorStrategic or Co-development Partner · 18 July 2025Collaboration to facilitate introduction of cefiderocol in Kenya. Shionogi and GARDP submitted Letter of Intent and project Concept Note to Kenyan Ministry of Health, which were accepted. Part of broader efforts for antimicrobial stewardship in Kenya.
  • BARDA (Biomedical Advanced Research and Development Authority)coreStrategic or Co-development Partner · 31 May 2024Qpex's partnership with BARDA under Other Transaction Authority (OTA) agreement (HHSO100201600026C) provides up to $132 million in federal funding for development of antibiotics to fight drug-resistant gram-negative infections. BARDA has awarded $92 million to date with technical support. The partnership has led to the first approved antimicrobial drug product under BARDA programs in 2017 and continues to advance Qpex's xeruborbactam-based products.
  • Shionogi & Co., Ltd.coreStrategic or Co-development Partner · 26 June 2023Shionogi acquired Qpex in 2023 to strengthen its antibiotic R&D capabilities and expand its anti-infective pipeline. The acquisition brought Qpex's expertise in antibiotic R&D along with its novel, internally discovered pipeline including xeruborbactam. Qpex continues to operate as a wholly owned Shionogi Group Company with expanded U.S.-based R&D operations.
  • GARDP (Global Antibiotic Research & Development Partnership)majorStrategic or Co-development Partner · 1 June 2022Landmark license and technology transfer agreement with GARDP to expand access to cefiderocol in 135 countries. Part of efforts to transform access to antibiotics in low- and middle-income countries.
  • Clinton Health Access Initiative (CHAI)majorGTM or Marketing Partner · 1 June 2022Collaboration agreement with CHAI as part of efforts to expand access to cefiderocol in low- and middle-income countries through pricing, distribution, and healthcare system support.
  • Brii BiosciencescoreStrategic or Co-development Partner · 19 January 2022Multi-product collaboration for development and commercialization of three Qpex products (including xeruborbactam-based products) in greater China (Taiwan, Hong Kong, Macau, and PRC). Qpex retained all other rights globally. Terms include upfront payment, success-based development, regulatory and commercial milestone payments, cost sharing in global development program, and tiered royalties on sales in Brii territory.
  • Monash UniversitymajorStrategic or Co-development Partner · 17 June 2021Research collaboration for development of QPX9003, a next-generation synthetic polymyxin. QPX9003 was discovered through NIAID-supported drug discovery collaboration with Professor Jian Li's team at Monash University's Antimicrobial Systems Pharmacology Laboratory. Funded by NIAID grants R01AI098771 and AI132154.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Qpex Biopharma competitors and assessment

Company assessment

Direct peers

  • Paratek Pharmaceuticals: Antibiotic developer of Nuzyra (omadacycline), acquired by Innoviva in 2023. Comparable as a small-cap antibiotic company with BARDA partnerships and novel mechanism anti-infectives targeting resistant pathogens.
  • Tetraphase Biosciences: Developer of Xerava (eravacycline), acquired by La Jolla Pharmaceutical Company in 2020. Directly comparable as a clinical-stage antibiotic company targeting multidrug-resistant infections, providing a cautionary commercial trajectory.
  • Melinta Therapeutics: Clinical and commercial-stage antibiotic company developing treatments for drug-resistant infections, including approved products like Baxdela and Orbactiv. Directly comparable as a small-cap anti-infectives company navigating the same challenging commercial economics.
  • Nabriva Therapeutics: Biopharmaceutical company that developed Xenleta (lefamulin), a first-in-class pleuromutilin antibiotic for community-acquired bacterial pneumonia. Comparable as a small anti-infectives company navigating commercial challenges post-approval.
  • Iterum Therapeutics: Clinical-stage pharmaceutical company developing sulopenem (oral and IV) for drug-resistant infections including complicated UTIs. Directly comparable as a small clinical-stage antibiotic developer with similar regulatory pathway challenges.
  • Entasis Therapeutics: Anti-infectives company developing targeted therapies for drug-resistant infections, including sulbactam-durlobactam for Acinetobacter. Acquired by Innoviva in 2022. Comparable as a precision antibiotic developer with similar AMR focus.

Others

  • Achaogen: Former biopharmaceutical company that developed Zemdri (plazomicin) and received BARDA funding similar to Qpex. Filed for bankruptcy in 2019 despite FDA approval, illustrating the structural commercial challenges facing novel antibiotic developers in the current market environment.

Broad incumbents

  • Shionogi & Co., Ltd. Japanese multinational pharmaceutical company and Qpex's parent organization. Develops and commercializes cefiderocol (Fetroja), the leading siderophore cephalosporin antibiotic. Comparable as the established global anti-infectives player whose resources and pipeline now include Qpex's assets.

Emerging players

  • Cidara Therapeutics: Biopharmaceutical company developing anti-infectives including Cloudbreak antiviral conjugates and rezafungin antifungal. Comparable as an early-commercial anti-infectives company with novel mechanism approaches to resistant pathogens.
  • VenatoRx Pharmaceuticals: Private clinical-stage pharmaceutical company developing novel antibiotics to combat drug-resistant infections, including ceftibuten-ledaborbactam combination. Comparable as an emerging antibiotic developer with similar beta-lactamase inhibitor approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Qpex Biopharma social profiles

Digital presence

Qpex Biopharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Qpex Biopharma leadership team

Management profile

Number of profiles

Profiles8 records

Qpex Biopharma funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Qpex Biopharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Qpex Biopharma

What does Qpex Biopharma do?

Qpex Biopharma is a clinical-stage biopharmaceutical company that discovers and develops a pipeline of novel anti-infective therapies targeting drug-resistant gram-negative bacteria. Its portfolio is anchored by xeruborbactam, an investigational ultra-broad-spectrum beta-lactamase inhibitor that enables both an IV product (OMNIvance) for inpatient hospital use and an oral product (ORAvance) for outpatient and community use. A third program, QPX9003, is a next-generation synthetic lipopeptide antibiotic designed to address highly drug-resistant Pseudomonas and Acinetobacter infections with an improved toxicity profile compared to existing polymyxins.

Is Qpex Biopharma a public or private company?

Qpex Biopharma is a private company. It is classified as corporate owned and is currently operating.

When was Qpex Biopharma founded?

Qpex Biopharma was founded in 2018. It employs 11 to 50 people.

Where is Qpex Biopharma based?

Qpex Biopharma is headquartered in San Diego, United States, in the North America region.

How does Qpex Biopharma make money?

Three revenue lines are on record. Antibiotic Development and Commercialization is the primary driver. The others are partnership and Licensing Revenue and government Contract Revenue.

Who are Qpex Biopharma's main competitors?

Direct peers on record are Paratek Pharmaceuticals, Tetraphase Biosciences, Melinta Therapeutics, Nabriva Therapeutics, Iterum Therapeutics and Entasis Therapeutics. Achaogen is listed as an others. Shionogi & Co., Ltd. is listed as a broad incumbent. Emerging players are Cidara Therapeutics and VenatoRx Pharmaceuticals.

Does Qpex Biopharma have an API?

No public API is recorded for Qpex Biopharma.

What industry is Qpex Biopharma in?

Qpex Biopharma's product category is Anti-infective Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAG, Infectious Disease & Antimicrobials Pharmaceuticals, with a secondary code of HLAAAFAG, Microbiome Modulating Small Molecules & Antibiotic Alternatives. Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
SdbnGareth Morgan Named President of Qpex Biopharma, Inc. – San Diego Biotechnology NetworkQpex Biopharma, a Shionogi Group company, announced the appointment of Gareth Morgan as President, succeeding Michael Dudley who has retired and stepped down from the roles of President and CEO. Morgan previously served as Senior Vice President and Global Head of Portfolio Management and AMR Policy at Shionogi Inc. Dr. Dudley will continue as a strategic advisor to both Qpex and Shionogi.PharmiWeb.comGareth Morgan Named President of Qpex Biopharma, Inc.Gareth Morgan has been appointed President of Qpex Biopharma, Inc., succeeding Michael Dudley who retired and stepped down as President and CEO. Morgan previously served as Senior Vice President and Global Head of Portfolio Management and AMR Policy at Shionogi Inc., the U.S. subsidiary of Shionogi & Co., Ltd., which acquired Qpex in 2023. Dudley will continue serving as a strategic advisor to both Qpex and Shionogi.PR NewswireBrii Biosciences Provides Corporate Updates and Reports 2023 Interim ResultsBrii Biosciences reported interim results for the first six months of 2023, with Other Income increasing 124.9% to RMB85.9 million driven by higher bank interest income and PRC government grants, while R&D expenses decreased 21.8% to RMB202.2 million following termination of COVID-19 programs. The company announced multiple clinical milestones including first patient dosing in a BRII-835 Phase 2 combination study for HBV functional cure, regulatory submissions for PreHevbri vaccine in APAC markets, and IND approval for BRII-877 in China. Brii Bio also executed strategic transactions acquiring exclusive global rights to BRII-179 from VBI Vaccines and BRII-693 from Qpex, while its partner Vir Biotechnology presented positive Phase 2 data for the HBV treatment program at EASL.PR NewswireBrii Biosciences Provides Latest Clinical Development and Corporate UpdatesBrii Biosciences announced strategic updates including extending its BRII-179 license to worldwide rights, acquiring exclusive rights to develop and commercialize PreHevbri® vaccine in Greater China and Asia Pacific, and acquiring global rights for BRII-693 from Qpex Biopharma, while appointing Dr. David Margolis as Chief Medical Officer. Clinical data showed that 16% of participants demonstrated sustained HBsAg loss 24 weeks post-treatment with BRII-835 + PEG-IFN-α, and a Phase 2 combination study achieved 90% of participants with HBsAg reduction below 10 IU/mL. The company expects data readouts from two Phase 2 HBV trials in the second half of 2023 and is working with FDA on a Phase 2 POC study protocol for postpartum depression treatment.PMLiVEShionogi to acquire Qpex Biopharma for approximately $140mShionogi has entered into a definitive agreement to acquire US-based Qpex Biopharma for approximately $140 million, gaining access to its three clinical-stage antibiotic programmes. The transaction includes an upfront payment of $100 million and up to $40 million in potential milestone payments, specifically targeting the development of xeruborbactam to combat antimicrobial resistance.BioSpaceShionogi Buys Qpex Biopharma for $140M, Expands Antimicrobial PipelineShionogi agreed to acquire San Diego-based Qpex Biopharma for up to $140 million, bringing its beta-lactamase inhibitor xeroborbactum into its pipeline. The deal includes $100 million upfront and $40 million contingent on milestones, giving Shionogi exclusive rights to the drug. Qpex has two clinical-stage programs targeting drug-resistant Gram-negative infections.ShionogiShionogi Further Extends Infectious Disease Innovation Platform with Planned Acquisition of Qpex Biopharma, Inc.Shionogi & Co., Ltd. has entered into a definitive agreement to acquire Qpex Biopharma, Inc., a San Diego-based clinical stage pharmaceutical company specializing in antimicrobial research. The acquisition involves an upfront payment of $100 million and potential milestone payments totaling $40 million, granting Shionogi global rights to Qpex's investigational beta-lactamase inhibitor, xeruborbactam. This move is intended to expand Shionogi’s pipeline for treating drug-resistant bacterial infections and augment its R&D capabilities.PR NewswireBrii Biosciences Announces Entry into Definitive Agreements from Sale of its Equity Interest in Qpex Biopharma and Acquiring Exclusive Global Rights for BRII-693Brii Biosciences entered into definitive agreements with Qpex Biopharma to acquire exclusive global rights for BRII-693, a novel lipopeptide antimicrobial candidate for difficult-to-treat MDR/XDR gram-negative bacterial infections, expanding beyond its existing Greater China rights. As part of the transaction, Brii Bio will return Greater China rights to QPX7728-based products to Qpex and receive approximately $24 million upfront upon closing of Qpex's acquisition by Shionogi, while also eliminating existing cost-share, milestone and royalty payment obligations. The company has submitted a pre-IND to China's NMPA and plans to prioritize global development of BRII-693, which received FDA Qualified Infectious Disease Product designation.PR NewswireQpex Biopharma Announces Exercise of $20 Million Option by BARDA under its Other Transaction Authority (OTA) Agreement to Advance Multiple Products into Clinical StudiesQpex Biopharma announced that the Biomedical Advanced Research and Development Authority (BARDA) has exercised a $20 million option under their Other Transaction Authority agreement to advance multiple antibiotic products into clinical studies. This funding supports the development of Qpex's portfolio aimed at treating drug-resistant gram-negative infections, including candidates such as ORAvance, OMNIvance, and QPX9003.